UCB released results of BE MOBILE 2 Phase 3 study of bimekizumab, a dual IL-17A and F inhibitor, in active ankylosing spondylitis. Showing at wk 16 superiority of BIM over PBO in ASAS40, BASDAI, ASDAS, ASAS partial remission https://t.co/Jt8mpxUCv0 https://t.co/T5QpJu8n6r